medigraphic.com
Colegio de Medicina Interna de México.

2018, Number 5

<< Back Next >>

Med Int Mex 2018; 34 (5)

Rational prescription of antibiotics: an urgent conduct

Isaías-Camacho JO, Salinas-Lezama E, Rodríguez-Weber FL, Díaz-Greene E

Language: Spanish
References: 36
Page: 762-770
PDF size: 450.48 Kb.


ABSTRACT

Antibiotic therapy has been a revolutionary way of seeing and practicing medicine. Regarding to its existence, millions of lives have been saved throughout history. Nevertheless, nowadays a vital topic is emerging: antibiotic resistance. Antibiotic resistance threatens the future of what once was the cure for a lot of many deadly diseases and now represents a challenge for all healthcare professionals. Antibiotic resistance is not a new concept, but the amount of resistant bacteria to certain antibiotics, geographical changes and locations affected with antibiotic resistance and broad-spectrum resistance is currently quickly increasing. There are more than fifteen antibiotic families whose mechanisms of action are involved in basic physiological and metabolic features of different bacteria. Of none of the latter has escaped any antibiotic.


REFERENCES

  1. OECD, Antimicrobial Resistance. [Online]. Available from: www.oecd.org/health/antimicrobial-resistance.htm [Accessed 24 Enero 2018].

  2. Levy S. The antibiotic paradox: How misuse of antibiotics destroys their curative powers. Clinical Infectious Diseases 2003;36(2).

  3. World Health Organization. [Online]. Available from: http:// www.who.int/mediacentre/factsheets/fs194/en/ [Accessed 24 Enero 2018].

  4. Marston H, et al. Antimicrobial resistance. JAMA 2016;316(11).

  5. Hoffman JM, et al. Projecting future drug expenditures 2007. Am J Health Syst Pharm 2007;64:298-314.

  6. Levy S, et al. Antibacterial resistance worldwide: causes, challenges and responses. Nature Medicine Supplement 2004;10(12).

  7. Levy SB. The challenge of antibiotic resistance. Sci Am 1998;278(3):46-53.

  8. Levy SB. Microbial resistance to antibiotics. An evolving and persistent problem. Lancet 1982;2:83-88.

  9. Barber M. Infection by penicillin resistant Staphylococci. Lancet 1948;2:641-644.

  10. Crofton J, et al. Streptomycin resistance in pulmonary tuberculosis. Br Med J 1948;2:1009-1015.

  11. Davey P, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013;4(CD003543).

  12. Centers for disease control and prevention, C.D.C [Online]. Available from: http://www.cdc.gov/drugresistance/ threat -report-2013/ [Accessed 24 January 2018].

  13. President’s council of advisors on science and technology. Report to the President on combating antibiotic resistance. [Online]. Available from: https://www.whitehouse. gov /sites/default/files/microsites/ostp/PCAST/pcast _amr_jan2015.pdf. [Accessed 24 January 2018].

  14. O’neill JIM. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. Rev Antimicrob Resistance 2014;1.

  15. Arias C, Murray, B. A New antibiotic and the evolution of resistance. NEJM 2015;372(12).

  16. Suda KJ, et al. A national evaluation of antibiotic expenditures by healthcare setting in the United States, 2009. J Antimicrob Chemother 2013;68(3):715-718.

  17. Fleming-Dutra KE, Hersh AL, Shapiro DJ, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA 2016;315(17):1864-1873.

  18. Morgan DJ, et al. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect Dis 2011;11(9):692-701.

  19. Levy SB. Balancing the drug resistance equation. Trends Microbiol 1994;2:341-342.

  20. Levy SB. The 2000 Garrod lecture. Factors impacting on the problem of antibiotic resistance. J Antimicrob Chemother 2002;49:25-30.

  21. Pray L. Antibiotic resistance, mutation rates and MRSA. Nature Educ 2008;1(1):30.

  22. Levy SB. Active efflux mechanisms for antimicrobial resistance. Antimicrob Agents Chemother 1992;36:695-703.

  23. Nikaido H. Multidrug efflux pumps of gram-negative bacteria. J Bacteriol 1996:178: 5853-5859.

  24. Paterson DL, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extendedspectrum β-lactamase production in nosocomial Infections. Ann Intern Med 2004;140:26-32.

  25. Nordmann, P. Poirel, L. Emerging carbapenemases in Gramnegative aerobes. Clin Microbiol Infect 2002;8:321-331.

  26. Wang H, et al. Genetic characterization of highly fluoroquinolone- resistant clinical Escherichia coli strains from China: role of acrR mutations. Antimicrob Agents Chemother 2001;45:1515-1521.

  27. Ben-David D, et al. Outcome of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18(1):54-60.

  28. Snitkin ES, et al; NISC Comparative Sequencing Program Group. Tracking a hospital outbreak of carbapenemresistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012;4(148).

  29. Liu YY, et al. Emergence of plasmid-mediated colistin resistance mechanism mcr-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016;16(2):161-168.

  30. McDonald LC, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353(23):2433- 2441.

  31. Magill SS, et al; Emerging Infections ProgramHealthcare- Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point prevalence survey of health care-associated infections. N Engl J Med 2014;370 (13):1198-1208.

  32. Schuetz P, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012;(9):CD007498.

  33. Sager R, et al. Procalcitonin-guided diagnosis and antibiotic stewardship revisited. BMC Medicine 2017;15:15.

  34. Nathwani D, Sneddon J. Practical guide to antimicrobial stewardship in hospitals. [Online]. Available from: http:// bsac.org.uk/wp-content/uploads/2013/07/Stewardship- Booklet-Practical-Guide-to-Antimicrobial-Stewardship-in- Hospitals.pdf . [Accessed 24 Enero 2018].

  35. Barbosa TM, et al. The impact of antibiotic use on resistance development and persistence. Drug Resist Updat 2000;3:303-311.

  36. Sandberg T, et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, openlabel and double-blind, placebo-controlled, non-inferiority trial. Lancet 2012;358:484-90.




2020     |     www.medigraphic.com